Copeptin improves prediction of treatment response in children with monosymptomatic nocturnal enuresis
An erratum to this article was published (Eur J Endocrinol, 2 Mar 2023 ↗)
Authors' conclusion
Our results indicate that, of our investigated parameters, plasma copeptin ratio is the best predictor for treatment response in children with MNE. Plasma copeptin ratio could thus be useful to identify children with the highest benefit of desmopressin treatment and improve individualized treatment of MNE.
Study context
- Population
- Children with monosymptomatic nocturnal enuresis (MNE) treated with desmopressin 120 µg daily (increased to 240 µg daily if clinically necessary)
- Participants
- 28 children
- Exposure
- Responders vs non-responders to desmopressin; prediction by baseline plasma copeptin ratio
- Outcome
- Reduction in number of wet nights with desmopressin, predicted by baseline plasma copeptin ratio (evening/morning copeptin)
- Follow-up
- 12 weeks
Main finding
As reported in the abstract
Prediction of treatment response by baseline copeptin ratio
- Best copeptin ratio cutoff
- 1.34
- Sensitivity
- 55.56%
- Specificity
- 94.12%
- AUC
- 70.6%
- P
- P = .07
Observational data: associations, not effects.
Further findings
Other predictors: wet nights at baseline and serum sodium
- Number of wet nights at baseline did not improve outcome prediction, alone or with copeptin
- P = 0.15
- Serum sodium did not improve outcome prediction, alone or with copeptin
- P = 0.11
Original publication
Copeptin improves prediction of treatment response in children with monosymptomatic nocturnal enuresis. Eur J Endocrinol. Published 16 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →